Rise in prevalence of neurological conditions, rise in awareness and diagnosis of CNS disorders, surge in research and development by key players, and technological advancements in drug delivery are expected to provide lucrative opportunities for the growth of the market during the forecast period.Wilmington, New Castle, Delaware, Feb. 23, 2024 (GLOBE NEWSWIRE) Allied Market Research published a report, titled, “Central Nervous System (CNS) Therapeutics Market by Disease Type (Neurovascular D
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced a poster presentation at the 34th International Symposium on ALS/MND, taking place in Basel, Switzerland from December 6 – 8, 2023. Presentation details Title: The two-pore potassium channel KCNK13 as a target to modulate neuroinflammation in Amyotrophic Lateral SclerosisOverview: Cerevance's unique NETSseq platform has the r
HOUSTON, TX / ACCESSWIRE / October 16, 2023 / Glioblastoma is the most aggressive type of brain cancer, with an average survival of only 14 to 16 months after diagnosis. There is currently no cure for glioblastoma, and it is a highly invasive tumor .
The increased incidence of chronic disease and corresponding increases in disability-adjusted life years, technical developments in medical equipment, and.
Trevena to Present at the JMP Securities Life Sciences Conference yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.